aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Myrobalan Therapeutics, founded with a mission to develop innovative therapeutic solutions for Central Nervous System (CNS) disorders, is deeply committed to restoring brain health. The company's vision revolves around harnessing the restorative potential of novel CNS therapeutics through mechanisms such as remyelination and anti-neuroinflammation. Their product pipeline focuses on addressing the underlying disease biology and mechanisms to effectively combat CNS disorders, aiming to improve patient outcomes in this challenging medical field.
Notable figures affiliated with Myrobalan Therapeutics include a dedicated team of scientists who drive the company's research and development efforts. The company has attracted significant interest from investors due to its promising approach and recent advancements. Key achievements include the successful progression of their therapeutic candidates through various stages of development, highlighting their potential impact on treating CNS disorders. Myrobalan Therapeutics continues to make strides in the biotech industry, contributing to the broader effort of finding effective treatments for debilitating neurological conditions.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Therapeutics
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Myrobalan Therapeutics founded?
Myrobalan Therapeutics was founded in 2021.
Where is Myrobalan Therapeutics’s headquarters located?
Myrobalan Therapeutics’s headquarters is located in Medford, MA, US.
When was Myrobalan Therapeutics’s last funding round?
Myrobalan Therapeutics’s most recent funding round was for $24M (USD) in January 2024.
How many employees does Myrobalan Therapeutics have?
Myrobalan Therapeutics has 16 employees as of Feb 4, 2024.
How much has Myrobalan Therapeutics raised to-date?
As of July 05, 2023, Myrobalan Therapeutics has raised a total of $24M (USD) since Jan 10, 2024.
Add Comparison
Total Raised to Date
$24M
USD
Last Update Jan 10, 2024
Last Deal Details
$24M
USD
Jan 10, 2024
Series A
Total Employees Over Time
16
As of Feb 2024
Myrobalan Therapeutics Address
Medford,
Massachusetts
02155
United States of America
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts